5 results on '"Alberto J. Montero"'
Search Results
2. Novel HER2–targeted therapies for HER2–positive metastatic breast cancer
- Author
-
Jame Abraham, Alberto J. Montero, and Siddharth Kunte
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Receptor, ErbB-2 ,Breast Neoplasms ,Capecitabine ,03 medical and health sciences ,chemistry.chemical_compound ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Breast cancer ,Trastuzumab ,Internal medicine ,medicine ,Humans ,Molecular Targeted Therapy ,030212 general & internal medicine ,Neoplasm Metastasis ,skin and connective tissue diseases ,Protein Kinase Inhibitors ,neoplasms ,Randomized Controlled Trials as Topic ,business.industry ,Margetuximab ,medicine.disease ,Metastatic breast cancer ,chemistry ,Trastuzumab emtansine ,030220 oncology & carcinogenesis ,Neratinib ,Female ,Pertuzumab ,business ,medicine.drug - Abstract
Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% of all breast cancers. Before the development of HER2-directed monoclonal antibodies, HER2-positive breast cancer was associated with a rather poor prognosis. With the advent of monoclonal HER2-targeting antibodies (trastuzumab and pertuzumab) and antibody-drug conjugates (trastuzumab emtansine [T-DM1] and trastuzumab deruxtecan), clinical outcomes for HER2-positive breast cancer have dramatically changed, and a greater proportion of patients in the nonmetastatic setting are cured. However, in the metastatic setting, resistance to anti-HER2 treatments still remains a major therapeutic challenge, underscoring the importance of developing novel HER2-directed therapies. Over the last year, there has been a dramatic shift in the current treatment paradigms for HER2-positive metastatic breast cancer, with recent U.S. Food and Drug Administration approvals of trastuzumab deruxtecan (DS-8201), neratinib, and tucatinib in combination with trastuzumab and capecitabine. The authors summarize recent phase 3 data with novel HER2-targeted therapies as well as phase 1 and 2 data with other novel HER2-targeting agents.
- Published
- 2020
3. Fractionated radioimmunotherapy with90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer
- Author
-
Kenneth Pennington, Daniel J. Lee, Alberto J. Montero, Seza A. Gulec, Tanios Bekaii-Saab, David V. Gold, Allyson J. Ocean, David M. Goldenberg, William A. Wegener, Bert H. O'Neil, Arif Sheikh, Heather Horne, John S. Kauh, Michael Holt, Michael J. Guarino, Stanley J. Goldsmith, Max Sung, Aldo N. Serafini, Timothy Manzone, and Nathan Hall
- Subjects
Adult ,Male ,Antimetabolites, Antineoplastic ,Radiation-Sensitizing Agents ,Cancer Research ,Pathology ,medicine.medical_specialty ,Neutropenia ,Maximum Tolerated Dose ,Combination therapy ,medicine.medical_treatment ,Radiation Dosage ,Deoxycytidine ,Article ,Pancreatic cancer ,medicine ,Carcinoma ,Humans ,Combined Modality Therapy ,Yttrium Radioisotopes ,Aged ,Aged, 80 and over ,business.industry ,Antibodies, Monoclonal ,Middle Aged ,Radioimmunotherapy ,medicine.disease ,Thrombocytopenia ,Gemcitabine ,Pancreatic Neoplasms ,Clinical trial ,Oncology ,Cancer research ,Female ,business ,Clivatuzumab ,Carcinoma, Pancreatic Ductal ,medicine.drug - Abstract
It has been demonstrated that the humanized clivatuzumab tetraxetan (hPAM4) antibody targets pancreatic ductal carcinoma selectively. After a trial of radioimmunotherapy that determined the maximum tolerated dose of single-dose yttrium-90-labeled hPAM4 ((90) Y-hPAM4) and produced objective responses in patients with advanced pancreatic ductal carcinoma, the authors studied fractionated radioimmunotherapy combined with low-dose gemcitabine in this disease.Thirty-eight previously untreated patients (33 patients with stage IV disease and 5 patients with stage III disease) received gemcitabine 200 mg/m(2) weekly for 4 weeks with (90) Y-hPAM4 given weekly in Weeks 2, 3, and 4 (cycle 1), and the same cycle was repeated in 13 patients (cycles 2-4). In the first part of the study, 19 patients received escalating weekly (90) Y doses of 6.5 mCi/m(2) , 9.0 mCi/m(2) , 12.0 mCi/m(2) , and 15.0 mCi/m(2) . In the second portion, 19 additional patients received weekly doses of 9.0 mCi/m(2) or 12.0 mCi/m(2) .Grade 3/4 thrombocytopenia or neutropenia (according to version 3.0 of the National Cancer Institute's Common Terminology Criteria for Adverse Events) developed in 28 of 38 patients after cycle 1 and in all retreated patients; no grade3 nonhematologic toxicities occurred. Fractionated dosing of cycle 1 allowed almost twice the radiation dose compared with single-dose radioimmunotherapy. The maximum tolerated dose of (90) Y-hPAM4 was 12.0 mCi/m(2) weekly for 3 weeks for cycle 1, with ≤9.0 mCi/m(2) weekly for 3 weeks for subsequent cycles, and that dose will be used in future trials. Six patients (16%) had partial responses according to computed tomography-based Response Evaluation Criteria in Solid Tumors, and 16 patients (42%) had stabilization as their best response (58% disease control). The median overall survival was 7.7 months for all 38 patients, including 11.8 months for those who received repeated cycles (46% [6 of 13 patients] ≥1 year), with improved efficacy at the higher radioimmunotherapy doses.Fractionated radioimmunotherapy with (90) Y-hPAM4 and low-dose gemcitabine demonstrated promising therapeutic activity and manageable myelosuppression in patients with advanced pancreatic ductal carcinoma.
- Published
- 2012
4. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?
- Author
-
Laurence R. Sands, Caio Rocha-Lima, Emerson Y. Chen, Ulas Darda Bayraktar, Soley Bayraktar, Floriano Marchetti, and Alberto J. Montero
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Time Factors ,Colorectal cancer ,medicine.drug_class ,medicine.medical_treatment ,Antineoplastic Agents ,Adenocarcinoma ,Antimetabolite ,Risk Factors ,Internal medicine ,medicine ,Humans ,Aged ,Neoplasm Staging ,Chemotherapy ,Univariate analysis ,business.industry ,Proportional hazards model ,Hazard ratio ,Cancer ,Middle Aged ,medicine.disease ,Oxaliplatin ,Surgery ,Chemotherapy, Adjuvant ,Colonic Neoplasms ,Female ,business ,medicine.drug - Abstract
BACKGROUND: It is unclear whether delays in commencing adjuvant chemotherapy after surgical resection of colon adenocarcinoma adversely impact survival. METHODS: Patients with stage II-III colon adenocarcinoma who received adjuvant chemotherapy at 2 centers were identified through the institutional tumor registry. Time to adjuvant chemotherapy, overall survival (OS), and relapse-free survival (RFS) were calculated from the day of surgery. Patients were dichotomized into early (time to adjuvant chemotherapy ≤60 days) and late treatment (time to adjuvant chemotherapy >60 days) groups. OS and RFS were compared using log-rank test and multivariate analysis by the Cox proportional hazards model. RESULTS: Of 186 patients included in the study, 49 (26%) had received adjuvant chemotherapy >60 days after surgical resection. Thirty percent of the delays were system related (eg, late referrals, insurance authorizations). Time to adjuvant chemotherapy >60 days was associated with significantly worse OS in both univariate analysis and a Cox proportional hazards model (hazard ratio, 2.17; 95% confidence interval, 1.08-4.36). Although difference in RFS between the 2 groups favored time to adjuvant chemotherapy 60 days after surgical resection of colon cancer is associated with worse OS. Cancer 2011;. © 2010 American Cancer Society.
- Published
- 2010
5. The natural history of breast carcinoma in patients withor = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study
- Author
-
L D O Richard Theriault, Vicente Valero, M. Spielmann, Monique Le, Alberto J. Montero, Ariane Dunant, Suzette Delaloge, Aman U. Buzdar, Roman Rouzier, Javier Garcia-Conde, Rodrigo Arriagada, Begoñia Bermejo, Ana Lluch, Aysegul A. Sahin, Sonja E. Singletary, R N Shu-Wan Kau, and Gabriel N. Hortobagyi
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Axillary lymph nodes ,Anthracycline ,Breast Neoplasms ,Disease-Free Survival ,Metastasis ,Institut Gustave Roussy ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Adjuvant therapy ,Humans ,Anthracyclines ,Retrospective Studies ,business.industry ,Carcinoma ,Cancer ,Middle Aged ,medicine.disease ,Prognosis ,Combined Modality Therapy ,Surgery ,Survival Rate ,Tamoxifen ,medicine.anatomical_structure ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,Axilla ,Hormonal therapy ,Female ,business ,Breast carcinoma ,Follow-Up Studies - Abstract
BACKGROUND The majority of patients with breast carcinoma with ≥ 10 metastatic axillary lymph nodes (ALNs) develop recurrent disease within 5 years from diagnosis. The purpose of the current study, performed retrospectively, was to characterize the natural history of this subset of patients, both before and after the advent of adjuvant anthracycline-based chemotherapy and tamoxifen. METHODS Retrospectively, patients with primary breast carcinoma (N = 882) with ≥ 10 metastatic ALNs, treated between 1954 and 1998, were selected from 3 institutions: The University of Texas M. D. Anderson Cancer Center (Houston, TX); the Institut Gustave Roussy (Villejuif, France); and Hospital Clinico Universitario (Valencia, Spain). All patient data had been registered prospectively in clinical databases. One group consisted of 314 patients treated with locoregional therapy alone (no adjuvant therapy) from 1954 to 1983. The second group included 568 patients who received adjuvant anthracycline-based chemotherapy between 1974 and 1998 with or without adjuvant tamoxifen. RESULTS The median follow-up time was 140 months. Disease-free survival rates at 15 and 20 years for the no adjuvant therapy and adjuvant therapy groups were 17% and 16% versus 26% and 24%, respectively. The overall survival rates at 20 years for the no adjuvant therapy and the adjuvant therapy groups were 9% and 21%, respectively. By multivariate analysis, the independent factors associated with survival in the adjuvant therapy group were tumor size and the number of metastatic lymph nodes. CONCLUSIONS The retrospective analysis suggested that adjuvant anthracycline-based chemotherapy and hormonal therapy have altered the natural history in this high-risk group of patients. However, despite such improvements, survival rates remained low, and innovative therapeutic approaches are, therefore, needed to improve clinical outcomes. Cancer 2005. © 2005 American Cancer Society.
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.